Market Place
Sourcing Support
BriaCell to Hold Virtual Investor Presentations on June 12 & 26
04 Jun 2025 //
GLOBENEWSWIRE
BriaCell Doses 1st Patient in Bria-OTS Ph1/2 Safety Study
27 May 2025 //
GLOBENEWSWIRE
BriaCell Abstracts Positive Data at ASCO 2025
23 May 2025 //
GLOBENEWSWIRE
BriaCell CEO Letter to Shareholders
20 May 2025 //
GLOBENEWSWIRE
BriaCell Reports Positive Phase 3 Data at AACR 2025
30 Apr 2025 //
GLOBENEWSWIRE
BriaCell Shows Survival and Clinical Benefit at AACR 2025
28 Apr 2025 //
GLOBENEWSWIRE
BriaCell Therapeutics Closes $13.8M Public Offering
28 Apr 2025 //
GLOBENEWSWIRE
BriaCell Therapeutics Prices $13.8M Public Offering
24 Apr 2025 //
GLOBENEWSWIRE
BriaCell Announces Four Clinical Data Presentations at ASCO 2025
23 Apr 2025 //
GLOBENEWSWIRE
BriaCell Ph 3 Study Enrollment Accelerating in (Bria-ABC) Cancer
22 Apr 2025 //
GLOBENEWSWIRE
BriaCell Phase 2 Data Beats Standard in HR+ Breast Cancer
16 Apr 2025 //
GLOBENEWSWIRE
BriaCell`s BriaPro Develops Antibodies for Cancer Target B7-H3
10 Apr 2025 //
GLOBENEWSWIRE
BriaCell to Present Data at 2025 AACR Conference
26 Mar 2025 //
GLOBENEWSWIRE
Second Board Recommends Continuing BriaCell’s Phase 3 Breast Cancer
20 Mar 2025 //
GLOBENEWSWIRE
BriaCell Therapeutics Announces Closing of Public Offering
05 Feb 2025 //
GLOBENEWSWIRE
BriaCell Therapeutics Corp Announces Result of Shareholder Meeting
05 Feb 2025 //
GLOBENEWSWIRE
BriaCell Therapeutics Announces Public Offering of Common Shares
03 Feb 2025 //
GLOBENEWSWIRE
BriaCell Therapeutics Announces Pricing of Public Offering
03 Feb 2025 //
GLOBENEWSWIRE
BriaCell Announces Resolution of Lung Metastasis in 1st Patient
03 Feb 2025 //
GLOBENEWSWIRE
BriaCell Announces Completion of 15:1 Share Consolidation
27 Jan 2025 //
GLOBENEWSWIRE
BriaCell Announces Proposed Effective Date of Share Consolidation
03 Jan 2025 //
GLOBENEWSWIRE
BriaCell Announces Rescheduling of Annual Meeting to Feb 5, 2025
03 Jan 2025 //
GLOBENEWSWIRE
BriaCell Announces AGM Materials & Voting Procedures Availability
17 Dec 2024 //
GLOBENEWSWIRE
BriaCell 2024 SABCS® Poster Highlights Bria-IMT™ Benefits
13 Dec 2024 //
GLOBENEWSWIRE
BriaCell Closes $5.5M Public Offering Successfully
13 Dec 2024 //
GLOBENEWSWIRE
BriaCell Presents Data in Metastatic Breast Cancer at SABCS
11 Dec 2024 //
GLOBENEWSWIRE
BriaCell Therapeutics Announces Proposed Public Offering
11 Dec 2024 //
GLOBENEWSWIRE
BriaCell Therapeutics Prices $5.5 Million Public Offering
11 Dec 2024 //
GLOBENEWSWIRE
BriaCell to Present SABCS® Spotlight Poster on Breast Cancer
26 Nov 2024 //
GLOBENEWSWIRE
BriaCell Provides Update to its Board of Directors
25 Nov 2024 //
GLOBENEWSWIRE
BriaCell Doses First Patient in Metastatic Breast Cancer Study
21 Nov 2024 //
GLOBENEWSWIRE
BriaCell Showcases Off-the-Shelf Immunotherapy at SITC 2024
08 Nov 2024 //
GLOBENEWSWIRE
BriaCell’s Overall Survival Data Selected for SABCS 2024 Spotlight
04 Nov 2024 //
GLOBENEWSWIRE
BriaCell Reports Survival Data For Metastatic Breast Cancer
22 Oct 2024 //
GLOBENEWSWIRE
BriaCell Provides Phase 3 Clinical Update In Metastatic Breast Cancer
15 Oct 2024 //
GLOBENEWSWIRE
BriaCell Therapeutics Announces Closing of $5 Million Offering
03 Oct 2024 //
GLOBENEWSWIRE
BriaCell Therapeutics Announces $5 Million Offering
01 Oct 2024 //
GLOBENEWSWIRE
BriaCell Announces FDA-Authorized Expanded Access Policy
18 Sep 2024 //
GLOBENEWSWIRE
BriaCell Therapeutics Announces Closing of $8.5 Million Offering
12 Sep 2024 //
GLOBENEWSWIRE
BriaCell Reports Positive Overall Survival (OS) in Metastatic Breast Cancer
11 Sep 2024 //
GLOBENEWSWIRE
BriaCell Therapeutics Announces $8.5 Million Offering
11 Sep 2024 //
GLOBENEWSWIRE
BriaCell Announces Positive FDA Pre-IND Meeting Results for Cancer
10 Sep 2024 //
GLOBENEWSWIRE
BriaCell Announces Presentation At SITC Annual Meeting
09 Sep 2024 //
GLOBENEWSWIRE
BriaCell Reports Quadrupled PFS In Metastatic Breast Cancer Patient
18 Jul 2024 //
GLOBENEWSWIRE
BriaCell Presents Clinical Efficacy Data at ASCO 2024
03 Jun 2024 //
GLOBENEWSWIRE
BriaCell Starts First-In-Human Bria-OTS„ Study In Metastatic Breast Cancer
30 May 2024 //
GLOBENEWSWIRE
Briacell Pfs Doubled Asco Data: Clinical Benefit In Ovarian Cancer
24 May 2024 //
GLOBENEWSWIRE
BriaCell Announces $5M Registered Direct Offering Closing
17 May 2024 //
GLOBENEWSWIRE
BriaCell Prices $5M Registered Direct Offering
15 May 2024 //
GLOBENEWSWIRE
BriaCell Confirms Strong Anti-Cancer Activity for Bria-OTS+ and Bria-PROS+
10 Apr 2024 //
GLOBENEWSWIRE
BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis
06 Mar 2024 //
GLOBENEWSWIRE
BriaCell Provides Update on Alleged Illegal Trading of Public Securities
27 Feb 2024 //
GLOBENEWSWIRE
BriaCell Announces Strong Clinical Data in Breast Cancer Patients
07 Feb 2024 //
GLOBENEWSWIRE
BriaCell Announces Lead Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing
06 Feb 2024 //
GLOBENEWSWIRE
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
30 Jan 2024 //
GLOBENEWSWIRE
BriaCell Reports 71% Nervous System Response Rate in Breast Cancer Patients
28 Dec 2023 //
GLOBENEWSWIRE
BriaCell Reports Clinical Benefit in ADC Refractory Patient Subset
20 Dec 2023 //
GLOBENEWSWIRE
BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells
06 Dec 2023 //
GLOBENEWSWIRE
BriaCell Highlights Benefit Data in Advanced Metastatic Breast Cancer
06 Dec 2023 //
GLOBENEWSWIRE
BriaCell Records Responder with Improvement of Eye-Bulging Metastatic Tumor
30 Nov 2023 //
GLOBENEWSWIRE
